BioCentury
ARTICLE | Company News

Sorrento gene/cell therapy, cancer news

June 8, 2015 7:00 AM UTC

Sorrento established TNK Therapeutics Inc., a wholly owned subsidiary to develop chimeric antigen receptor tumor-attacking Neukoplasts (CAR-TNKs) and other cellular and immunotherapies for solid tumor...